DOCSLIB.ORG

Secondary Adrenal Suppression and Cushing's Syndrome Caused By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Secondary Adrenal Suppression and Cushing's Syndrome Caused By Secondary adrenal suppression and Cushing’s syndrome caused by ritonavir-boosted effects of inhaled fluticasone, injected triamcinolone and topical clobetasol: A case series NJ Marshall1, K Gurazada2, P Bouloux2, B Khoo2, and MA Johnson1 1. Ian Charleson Centre for HIV medicine, Royal Free London NHS Foundation Trust 2. Department of Endocrinology, Royal Free London NHS Foundation Trust Background Fluticasone inhaled/nasal (2) Practice Points • Most glucocorticoids are hepatically metabolised but Fig 1: MRI Spine showing osteoporotic vertebral crush General: there is very limited information on the extent to which fractures in thoracic and lumbar spine and steroid hump • Interactions between glucocorticoids and ritonavir are this occurs and which CYP enzymes are responsible common and can lead to significant morbidity for this • Due to CYP inhibition by ritonavir, there is likely to be • Fluticasone is known to be metabolised by CYP 3A4, an increase in systemic exposure from most and drug-drug interactions (DDI) between ritonavir glucocorticoids irrespective of route of administration, and inhaled or nasal formulations are well described, with the possible exception of beclometasone leading to accumulation of glucocorticoid and • A tapering steroid dose may be required after exposure increasing the risk of iatrogenic Cushing’s syndrome to short term oral glucocorticoid due to the increased and suppression of the Hypothalamic-Pituitary- exposure related to DDI with ritonavir Adrenal axis (HPA-A) • HIV diagnoses and potential for interaction should be • There are 7 cases in the literature describing the stated on all referral letters, especially when referring potential interaction of triamcinolone showing similar patients for X-ray guided glucocorticoid injections outcomes, including avascular necrosis of femoral heads of femur in 2 cases Fig 4: Potential interactions of ritonavir with available • We describe a series of patients on ritonavir-based Triamcinolone injection corticosteroid preparations (author’s opinion) ART who developed evidence of adrenal suppression Drug Injection PO Inhaled Nasal Top • Six patients on PI/r-based HAART presented after Fluticasone na ■ receiving triamcinolone injections Budesonide na ■ ■ / ■ na Methods • 4/6 presented with signs of Cushing’s syndrome and Triamcinolone na na ■ adrenal suppression Mometasone ■ na ■ ■ ■ • Case series based on 11 patients presenting to the Methylpred ■ ■ na na na • 2/6 were identified very early after injection, before HIV clinic who are known or subsequently discovered Prednisolone ■ ■ na na ■ symptoms of glucocorticoid excess had developed. In to have received a variety of glucocorticoids whilst Hydrocortisone ■ ■ na na one case (patient 6) ATV/r was switch to raltegravir taking ritonavir-based ART leading to adverse drug- Dexamethasone ■ ■ na na ■ within 3 weeks of injection to expedite clearance of Beclometasone drug interactions (DDI) triamcinolone. Patient 3 required PI-based HAART Key: Contraindicated/risk of severe AE, ■ Caution, minor risk, na not applicable due to resistance Inhaled steroids and ritonavir: • Triamcinolone injection was prescribed via the pain Fluticasone inhaled/nasal (1) • Fluticasone inhaler and nasal sprays should be team, neurology, rheumatology and orthopaedic avoided wherever possible • 4 patients presented with symptoms of adrenal specialities, typically from with the hospital • Beclometasone is the preferred inhaled steroid due to suppression after exposure to inhaled (n=4) and/or lack of observed interactions nasal (n=2) fluticasone whilst on ritonavir-based ART • When beclometasone is ineffective then inhaled • One patient (ID 7) presented with impaired mobility budesonide may be an alternative but used at the due to back pain and proximal muscle weakness, Clobetasol cream lowest dose with titration, counselling, and monitoring which on imaging showed osteoporotic vertebral crush of cortisol fractures in thoracic and lumbar spine (fig 1) • One black-African female presented with Cushing’s syndrome after months of exposure to topical • Steroid sparing therapies should be considered secondary to inhaled fluticasone use with LPV/r. He presented with cushingoid appearance with central clobetasol, used for skin whitening. It is unclear to Injectable steroids: what extent the cream is absorbed but her PI-based obesity and truncal striae, and developed CMV • Triamcinolone should be avoided for patients regimen may have contributed to adrenal suppression viraemia, transaminitis, and influenza AH1N1 during prescribed ritonavir, and potentially other CYP 3A4 inpatient admission inhibitors such as the HCV NS3 protease inhibitors Fig 2: Triamcinolone patients (n=6); HPA axis recovery over 6 months • Methylprednisolone may be a suitable alternative, 350 although there is limited data on DDI and safety • A morning cortisol should be performed 2 weeks after 250 any glucocorticoid injection with referral to endocrinology if measured cortisol is low ART modification: 150 Triamcinolone Injection ID • If a glucocorticoid is indicated with high risk of DDI then 1 2 switching to a PI/r sparing regimen should be Serum cortisol (nmol/L) Serum cortisol 50 3 considered for the duration of glucocorticoid exposure 4 5 • If a PI/r sparing regimens are not possible due to 6 0 significant HIV resistance, a discussion should be had 0m 1m 2m 3m 4m 5m 6m over choice and dose of glucocorticoid, plus planned Cortisol of <80nmol/L: adrenal suppression requiring replacement. Cortisol 80-450nmol/L: possible adrenal suppression, investigate with SST. Cortisol >450nmol/L: adequate response, no further investigation follow up between the HIV team and referring clinician Fig 3: Patient exposed to triamcinolone, fluticasone or clobetsol Hydrocortisone Route of exposure / Duration of ID Age/Sex Glucocorticoid ART regimen Presented with Effect of interaction replacement Change in ART Dose exposure therapy given Conclusions ATV/r/ Fatigue, dizziness on standing, chest 1 47 M Triamcinolone IA 40mg 2 doses Adrenal suppression No No TDF/TFC infection Nausea, vomiting, diarrhea, urine • As we increasingly involve primary care and other 2 47 M Triamcinolone IA 80mg stat LPV/r Adrenal suppression No No infection, worsened type 2 diabetes specialties in our patient’s care we will need to be ATV/r/ 3 65 M Triamcinolone IA 40mg 2 doses No symptoms as early recognition Adrenal suppression Yes No MVC/RAL vigilant for the potential of these interactions, and DRV/r/ Weight gain, moon face, acne, oral Cushing’s syndrome with 4 39 F Triamcinolone IA 40mg 2 doses Yes DRV/r RAL at month 4 provide colleagues and patient alike with information TDF/FTC OD candiasis, worsening depression adrenal suppression ATV/r/ resources for drug interactions 5 42 M Triamcinolone IA 80mg Stat Severe proximal myopathy Adrenal Suppression No No NVP/TDF ATV/r/ • When patients on ritonavir-based HAART require 6 42 M Triamcinolone IA 40mg 2 doses No symptoms as early recognition Adrenal Suppression Yes ATV/r RAL at wk3 TDF/FTC glucocorticoids which interact, a multi-disciplinary Back pain (Osteoporotic crush fracture, LPV/r/ Cushing’s syndrome with 7 55 M Fluticasone INH 1000mcg/day 2 yrs see image 1) with overt Cushing’s Yes No approach is necessary to avoid increased morbidity adrenal suppression TDF/FTC syndrome, Aspergilloma Weight gain, plethoric puffy face, ATV/r/ Cushing’s syndrome with 8 45 M Fluticasone INH 1000mcg/day 2 yrs centripetal obesity, striae, proximal Yes, short term No adrenal suppression TDF/TFC weakness ATV/r/ Tiredness, plethoric facies after ritonavir 8 45 M Fluticasone INH 1000mcg/day 7 days Adrenal Suppression Yes, short term No References TDF/TFC re-commenced INH 400mcg/day + Months ATV/r/ Cushing’s syndrome with 9 71 M Fluticasone Overt Cushing’s syndrome No No nasal spray + weeks TDF/FTC adrenal suppression • Foisy MM et al. HIV medicine 2008;9:389-396 • Mollman et al. Eur J clin pharmacol 1998;53:459-467; Fluticasone / Nasal spray / LPV/r/ 10 42 F 4 weeks No symptoms as early recognition Adrenal suppression No No • Ramanathan R et al. CID 2008;475 betamethasone 0.1% cream SAQ/NVP • Sarita B et al. CROI 2012, Seattle, Session 109, poster 611 Skin whitening Several ATV/r/ Cushing’s syndrome with • Sarita B et al. CROI 2012, Seattle, Session 109, poster 610 11 72 F Clobetsasol Overt Cushing's syndrome Yes No cream months ABC/3TC adrenal suppression • www.hivclinic.ca accessed 10/4/2012 .
Load more

Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Australian Public Assessment Report for Clobetasol Propionate
    Australian Public Assessment Report for Clobetasol propionate Proprietary Product Name: Clobex Sponsor: Galderma Australia Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Composition for Rectal Administration Combined with an Oral Alpha-Lipoic
    (19) & (11) EP 2 162 125 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/136 (2006.01) A61K 31/01 (2006.01) 19.10.2011 Bulletin 2011/42 A61P 1/00 (2006.01) A61K 45/06 (2006.01) A61K 31/56 (2006.01) A61K 31/573 (2006.01) (2006.01) (21) Application number: 08768441.1 A61K 31/606 (22) Date of filing: 13.06.2008 (86) International application number: PCT/US2008/007401 (87) International publication number: WO 2008/156671 (24.12.2008 Gazette 2008/52) (54) Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease Zusammensetzung zur rektalen Verabreichung kombiniert mit einer oralen Zusammentzung enthaltend alpha Liponsäure zur Behandlung von entzündlicher Darmerkrankung Composition pour l’administration rectale en combinaison avec une composition orale de l’ acide alpha- lipoique pour le traitment des maladies intestinales inflammatoires (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR EP-B1- 0 671 168 WO-A2-02/089796 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT US-A- 4 657 900 US-A- 5 082 651 RO SE SI SK TR US-A- 5 378 470 (30) Priority: 13.06.2007 US 934505 P • MULDER CJ. ET AL.: ’Beclomethasone 06.02.2008 US 63745 P dipropionate (3mg) versus 5- aminosalicylic acid (2g) versus the combination of both (3mg/2g)as (43) Date of publication of application: retention enemas in active ulcerative proctitis’ 17.03.2010 Bulletin 2010/11 EUR.J.GASTROENTEROL HEPATOL vol.
    [Show full text]
  • Inhaled Corticosteroid (ICS) Only – Metered Dose Inhalers (MDI)
    Categorisation and Formulary Choices of Inhaled Corticosteroids for Adults Inhaled Corticosteroid (ICS) only – Metered Dose Inhalers (MDI) MDI Beclometasone dipropionate Use with a compatible Fluticasone Propionate spacer device Prescribe by BRAND Clenil Modulite® Qvar®(extrafine) Qvar®(extrafine) Flixotide® Evohaler MDI Easi-Breathe Low Dose 100mcg, two puffs twice a 50 mcg, two puffs twice a day 50 mcg, two puffs twice a day 50 mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) ≤400mcg BDP) £4.45/month £4.72/month £4.64/month £5.44/month Medium Dose 200mcg, two puffs twice a 100 mcg, two puffs twice a day 100 mcg, two puffs twice a day 125mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) 400-1000mcg BDP) £9.70/month £10.33/month £10.17/month £12.50/month High Dose 250mcg, two puffs twice a 100 mcg, four puffs twice a day 100 mcg, four puffs twice a day 250mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) >1000mcg BDP) £9.77/month £20.66/month £20.34/month £20.00/month Simultaneous specialist OR referral recommended 250mcg four puffs, twice a day (200 dose) £19.55/month Prices correct as per Drug Tariff and DM&D December2018 1st line choices (dark green, solid border) 2nd line choices (light green, dashed border) Approved by Hertfordshire Medicines Management Committee – October 2018 Inhaled Corticosteroid (ICS) only – Dry Powder Inhalers (DPI) Beclometasone DPI dipropionate Budesonide Fluticasone Propionate Prescribe
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis
    THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie Arsonnaud Owing to its anti-inflammatory, antipruritic, soriasis is a lifelong condition, with onset vasoconstrictive, and immune-modulating prop- occurring at any time throughout life. It erties, clobetasol propionate is used to treat P affects men and women equally, and almost all psoriasis. This study was conducted to evaluate races in varying rates of frequency are affected. Pso- the efficacy, safety, and cosmetic acceptability riasis usually first appears between the ages of 15 of clobetasol propionate lotion compared with and 30 years and may occur anywhere on the body. its vehicle and with clobetasol propionate Psoriasis is an inherited condition; however, cream in the treatment of moderate to severe both genetic and environmental factors play an plaque-type psoriasis. important role in its onset and course. The condi- A total of 222 patients were treated. After tion has a considerable impact on quality of life, 4 weeks of treatment, clobetasol propionate with patients complaining about the messiness of lotion was more efficient than vehicle lotion and the topical agents used to treat the condition and of equivalent efficacy as clobetasol propionate the profound psychological impact of the treat- cream. Cosmetic acceptability was significantly ments and the condition.1-5 better with clobetasol propionate lotion than with Clobetasol propionate is known for its anti- clobetasol propionate cream. Clobetasol propi- inflammatory, antipruritic, vasoconstrictive, and onate lotion was efficient, safe, and well toler- immune-modulating properties and is currently ated and offers a significantly higher cosmetic used in the treatment of certain hyperproliferative advantage in the treatment of moderate to or inflammatory dermatoses, including psoriasis severe plaque-type psoriasis compared with and atopic dermatitis.
    [Show full text]